Testing a new method to predict breast cancer recurrence risk
Validation of the MHC II Immune Activation Assay in Breast Cancer
This study is looking to create a simple test that helps patients with triple negative and HER2+ breast cancer understand their risk of the cancer coming back, so they can avoid harsh treatments if they don't need them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10898822 on NIH RePORTER |
What this research studies
This research focuses on developing a clinical biomarker test to assess the risk of recurrence in patients with triple negative breast cancer (TNBC) and HER2+ breast cancer. Currently, these patients undergo aggressive chemotherapy without knowing their prognosis, leading to unnecessary side effects. The study utilizes a multigene expression assay to measure the MHC Class II antigen presentation pathway and tumor infiltrating leukocytes in breast tumor samples. By generating an Immune Activation Score, the research aims to identify patients with a low risk of recurrence, potentially allowing for less aggressive treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative or HER2+ breast cancer who are currently facing aggressive chemotherapy treatments.
Not a fit: Patients with estrogen receptor-positive breast cancer may not benefit from this research as it specifically targets TNBC and HER2+ subtypes.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for breast cancer patients, reducing unnecessary chemotherapy and its side effects.
How similar studies have performed: Previous research has shown promise in using similar biomarker approaches for other breast cancer subtypes, indicating potential for success in this novel application.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Varley, Katherine Elena — University of Utah
- Study coordinator: Varley, Katherine Elena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.